May 1st 2020
By The Center for Biosimilars
The reasons for biosimilar brand preference in a recent rituximab study were unclear, but investigators said it is clear that savings were a likely factor.
April 27th 2020
By Tony Hagen
Henlius Biotech said its manufacturing facility has met European standards for production of its trastuzumab biosimilar candidate, which the company said is "a passport" for potential commericialization across the globe.
April 26th 2020
By Skylar Jeremias
A retrospective, postmarketing study demonstrates higher incidence of joint and bone pain, neutropenia with certain filgrastim biosimilars, compared with Neupogen.
April 25th 2020
Cheryl Larson, president and chief executive officer of the Midwest Business Group on Health, discusses the sticker shock of rising specialty drug costs and how biosimilars are going to be incorporated into efforts to push back against this medical inflation.
April 22nd 2020
Biosimilar pricing is not as simple as a manufacturer's stated discount to the reference product cost, according to Adam Brufsky, MD, PhD, FACP, of the University of Pittsburgh Medical Center (UPMC) in Pennsylvania.
Although the coronavirus disease 2019 (COVID-19) pandemic has put a burden on the economy and the healthcare system in particular, Kashyap Patel, MD, believes that the crisis will likely speed up biosimilar uptake in the United States.
Many additional biosimilars could be on the market by 2025, said presenters at the Academy of Managed Care Pharmacy eLearning Days virtual meeting.
April 20th 2020
Posters presented at the Academy of Managed Care Pharmacy (AMCP) eLearning Days meeting this week from April 20 to 24 reveal important data on biosimilar utilization management, switching, and affordability.
April 17th 2020
A percentage of oncology pharmacy practitioners report their guidance on biosimilars is influential with clinicians, but many feel their knowledge of biosimilars is deficient in a number of important areas.
April 15th 2020
In partnership with Samsung Bioepis, Merck has launched the trastuzumab biosimilar Ontruzant, which marks the fifth trastuzumab biosimilar available on the US market.
